# Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

> **NCT03620955** · — · UNKNOWN · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 1000 (estimated)

## Conditions studied

- Risk-directed Therapy
- Cytogenetic Abnormality
- Molecular Abnormality
- MRD

## Interventions

- **OTHER:** Justified risk stratification based on MRD after three course chemo therapy

## Key facts

- **NCT ID:** NCT03620955
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-10
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2019-11-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03620955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03620955, "Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03620955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*